GENERAL
US FDA Expands Glenmark RYALTRIS Approval To Children Above 6 Years
Glenmark Specialty S A has received approval from the US Food and Drug Administration (US FDA) to expand the use of its allergy treatment RYALTRIS nasal spray for pediatric patients aged 6 to less than 12 years suffering from Seasonal Allergic Rhinitis (SAR). The approval broadens the eligible patient population for the drug in the […]
CW Bureau
·
Jul 21, 2026
GENERAL
Lupin Carves Out 2 Cancer Therapy Programmes Into New US Venture
Global pharmaceutical major Lupin Ltd has announced the strategic spin-out of two of its oncology programmes into Kaveri Therapeutics Inc., a US-based clinical-stage oncology company, in a move aimed at accelerating the global development of targeted cancer therapies. Independent platform for oncology development The spin-out will be executed through Lupin Inc., the company’s wholly owned […]
CW Bureau
·
Jul 21, 2026
GENERAL
Sun Pharma Gets South Africa Nod For Generic Semaglutide Injection
Sun Pharmaceutical Industries Ltd (Sun Pharma) has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of Semaglutide injection for the treatment of adults with inadequately controlled Type 2 diabetes mellitus. The approval marks South Africa as the second market after India where Sun Pharma has […]
CW Bureau
·
Jul 15, 2026
GENERAL
Lupin Banks On Biosimilars, Specialty Medicines To Power Next Expansion
Lupin Ltd is stepping up its focus on biosimilars, specialty medicines, complex generics and artificial intelligence (AI) as it builds the next phase of its growth strategy, according to Chief Executive Officer Vinita Gupta and Managing Director Nilesh Gupta in a joint message to shareholders in the company’s Annual Report 2026. The leadership said years […]
CW Bureau
·
Jul 14, 2026
GENERAL
Pfizer Focuses On Vaccines, Internal Medicine To Power Growth In India
Pfizer strengthened its growth momentum during the year In India through strong execution across its vaccines, internal medicine and hospital businesses, supported by new product launches, strategic partnerships and sustained market leadership across key therapeutic segments. In a message to shareholders in the company’s Annual Report 2026, Pfizer Ltd Managing Director Meenakshi Nevatia said the […]
CW Bureau
·
Jul 7, 2026
GENERAL
Biocon Partner Bags Malaysia Insulin Contracts Worth Over MYR 225 Mn
Biocon Ltd, an innovation-led global biopharmaceutical company, said its long-standing partner, Duopharma Biotech Berhad, through its wholly owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin supply contracts from Malaysia’s Ministry of Health (MoH) worth more than MYR 225 million. Under the contracts, Biocon’s Malaysian subsidiary, Biocon Sdn. Bhd., will supply short-acting recombinant human […]
CW Bureau
·
Jun 24, 2026
GENERAL
Indian Pharma Firms To Gain Up To $5 Bn From Global Patent Cliff: CareEdge
Indian pharmaceutical companies are poised to benefit from a major global patent expiry cycle, with drugs generating nearly $142 billion in sales in CY25 set to lose exclusivity between 2026 and 2030, according to a report by CareEdge Ratings. The report estimates that the upcoming patent cliff could create a market opportunity of over $30-40 […]
CW Bureau
·
Jun 19, 2026
GENERAL
Glenmark Pharma Launches Generic Vancomycin Injection In US Market
Glenmark Pharmaceuticals has announced the launch of Vancomycin Hydrochloride for Injection USP in the U.S. market, expanding its injectable portfolio amid growing demand for affordable hospital medicines. The company said the product will be available in 500 mg/vial and 1 g/vial strengths through its U.S.-based arm, Glenmark Pharmaceuticals Inc., USA. Targets $37.9 million market opportunity […]
CW Bureau
·
May 18, 2026
